Piper Sandler Boosts Masimo (NASDAQ:MASI) Price Target to $215.00

Masimo (NASDAQ:MASI) had its target price upped by Piper Sandler from $210.00 to $215.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s price target would suggest a potential upside of 14.88% from the company’s previous close.

MASI has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday. Wells Fargo & Company increased their target price on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday. Stifel Nicolaus restated a “buy” rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Raymond James boosted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $194.80.

Masimo Stock Up 10.4 %

Shares of NASDAQ MASI traded up $17.61 during trading hours on Wednesday, hitting $187.15. The stock had a trading volume of 767,065 shares, compared to its average volume of 490,711. The firm’s 50-day moving average price is $172.56 and its two-hundred day moving average price is $152.84. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a 52 week low of $101.61 and a 52 week high of $190.07. The company has a market capitalization of $10.02 billion, a P/E ratio of 129.37 and a beta of 1.02.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Analysts anticipate that Masimo will post 4.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Masimo

A number of hedge funds have recently made changes to their positions in MASI. Jones Financial Companies Lllp bought a new stake in shares of Masimo during the 4th quarter worth approximately $27,000. UMB Bank n.a. grew its stake in Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares during the last quarter. Trust Co. of Vermont purchased a new position in Masimo during the 4th quarter worth approximately $33,000. Blue Trust Inc. grew its position in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 64 shares during the period. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.